Compass Therapeutics Stock Net Income
| CMPX Stock | USD 5.90 0.37 5.90% |
As of the 24th of January, Compass Therapeutics shows the Downside Deviation of 3.79, risk adjusted performance of 0.1281, and Mean Deviation of 3.01. Compass Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Compass Therapeutics Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -44.4 M | -46.7 M | |
| Net Loss | -35.3 M | -37.1 M | |
| Net Loss | -44.4 M | -46.7 M | |
| Net Loss | (0.32) | (0.34) | |
| Net Income Per E B T | 1.15 | 1.10 |
Compass | Net Income | Build AI portfolio with Compass Stock |
Latest Compass Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Compass Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Compass Therapeutics financial statement analysis. It represents the amount of money remaining after all of Compass Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Compass Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (49.38 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Compass Net Income Regression Statistics
| Arithmetic Mean | (41,952,346) | |
| Coefficient Of Variation | (26.90) | |
| Mean Deviation | 6,515,900 | |
| Median | (38,286,000) | |
| Standard Deviation | 11,284,681 | |
| Sample Variance | 127.3T | |
| Range | 52.7M | |
| R-Value | (0.34) | |
| Mean Square Error | 119.9T | |
| R-Squared | 0.12 | |
| Significance | 0.18 | |
| Slope | (764,580) | |
| Total Sum of Squares | 2037.5T |
Compass Net Income History
Other Fundumenentals of Compass Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Compass Therapeutics Net Income component correlations
Compass Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Compass Therapeutics is extremely important. It helps to project a fair market value of Compass Stock properly, considering its historical fundamentals such as Net Income. Since Compass Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Compass Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Compass Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Therapeutics. If investors know Compass will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compass Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Compass Therapeutics is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Compass Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Therapeutics' market value can be influenced by many factors that don't directly affect Compass Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compass Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Compass Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compass Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Compass Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Compass Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Compass Therapeutics.
| 10/26/2025 |
| 01/24/2026 |
If you would invest 0.00 in Compass Therapeutics on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Compass Therapeutics or generate 0.0% return on investment in Compass Therapeutics over 90 days. Compass Therapeutics is related to or competes with Fulcrum Therapeutics, 4D Molecular, Ocugen, Bicycle Therapeutics, Gossamer Bio, Lexicon Pharmaceuticals, and Monopar Therapeutics. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-... More
Compass Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Compass Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Compass Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.79 | |||
| Information Ratio | 0.144 | |||
| Maximum Drawdown | 16.14 | |||
| Value At Risk | (5.86) | |||
| Potential Upside | 7.61 |
Compass Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compass Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Compass Therapeutics' standard deviation. In reality, there are many statistical measures that can use Compass Therapeutics historical prices to predict the future Compass Therapeutics' volatility.| Risk Adjusted Performance | 0.1281 | |||
| Jensen Alpha | 0.5892 | |||
| Total Risk Alpha | 0.2686 | |||
| Sortino Ratio | 0.1501 | |||
| Treynor Ratio | 0.8947 |
Compass Therapeutics January 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1281 | |||
| Market Risk Adjusted Performance | 0.9047 | |||
| Mean Deviation | 3.01 | |||
| Semi Deviation | 3.2 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 610.57 | |||
| Standard Deviation | 3.96 | |||
| Variance | 15.65 | |||
| Information Ratio | 0.144 | |||
| Jensen Alpha | 0.5892 | |||
| Total Risk Alpha | 0.2686 | |||
| Sortino Ratio | 0.1501 | |||
| Treynor Ratio | 0.8947 | |||
| Maximum Drawdown | 16.14 | |||
| Value At Risk | (5.86) | |||
| Potential Upside | 7.61 | |||
| Downside Variance | 14.39 | |||
| Semi Variance | 10.26 | |||
| Expected Short fall | (3.38) | |||
| Skewness | 0.2442 | |||
| Kurtosis | (0.04) |
Compass Therapeutics Backtested Returns
Compass Therapeutics appears to be moderately volatile, given 3 months investment horizon. Compass Therapeutics secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17 % return per unit of risk over the last 3 months. By analyzing Compass Therapeutics' technical indicators, you can evaluate if the expected return of 0.67% is justified by implied risk. Please makes use of Compass Therapeutics' Risk Adjusted Performance of 0.1281, mean deviation of 3.01, and Downside Deviation of 3.79 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Compass Therapeutics holds a performance score of 13. The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Compass Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Compass Therapeutics is expected to be smaller as well. Please check Compass Therapeutics' treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Compass Therapeutics' price patterns will revert.
Auto-correlation | 0.74 |
Good predictability
Compass Therapeutics has good predictability. Overlapping area represents the amount of predictability between Compass Therapeutics time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Compass Therapeutics price movement. The serial correlation of 0.74 indicates that around 74.0% of current Compass Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.74 | |
| Spearman Rank Test | 0.63 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Compass Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Compass Therapeutics reported net income of (49.38 Million). This is 114.47% lower than that of the Biotechnology sector and 170.49% lower than that of the Health Care industry. The net income for all United States stocks is 108.65% higher than that of the company.
Compass Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compass Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics of similar companies.Compass Therapeutics is currently under evaluation in net income category among its peers.
Compass Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Compass Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Compass Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Compass Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Compass Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Compass Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Compass Therapeutics' value.| Shares | Fmr Inc | 2025-06-30 | 4.1 M | Blue Owl Capital Holdings Lp | 2025-06-30 | 2.6 M | Geode Capital Management, Llc | 2025-06-30 | 2.3 M | Jpmorgan Chase & Co | 2025-06-30 | 2.1 M | State Street Corp | 2025-06-30 | 2 M | Silverarc Capital Management, Llc | 2025-06-30 | 1.2 M | Millennium Management Llc | 2025-06-30 | 851.2 K | Northern Trust Corp | 2025-06-30 | 734.7 K | Caption Management, Llc | 2025-06-30 | 725.5 K | Orbimed Advisors, Llc | 2025-06-30 | 15.2 M | Tang Capital Management Llc | 2025-06-30 | 13.5 M |
Compass Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 839.36 M | ||||
| Shares Outstanding | 177.86 M | ||||
| Shares Owned By Insiders | 11.18 % | ||||
| Shares Owned By Institutions | 83.77 % | ||||
| Number Of Shares Shorted | 21.59 M | ||||
| Price To Book | 5.01 X | ||||
| Price To Sales | 439.25 X | ||||
| Revenue | 850 K | ||||
| EBITDA | (54.87 M) | ||||
| Net Income | (49.38 M) | ||||
| Cash And Equivalents | 132.02 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 6.63 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.36 X | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Short Ratio | 11.64 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Target Price | 13.23 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 1.12 B | ||||
| Total Asset | 140.4 M | ||||
| Retained Earnings | (364.68 M) | ||||
| Working Capital | 123.88 M | ||||
| Net Asset | 140.4 M |
About Compass Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Compass Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.